4 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Prep Biopharm Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production PrEP-001 6.4 mg, PrEP-001 3.2 mg, Placebo - Upper Respiratory Tract Infections | Phase 1 | Completed | Prep Biopharm Limited | 20 | 2017-05-08 | 2017-07-02 |
| A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16 PrEP-001, Placebo - Viral Upper Respiratory Tract Infection | Phase 2 | Completed | Prep Biopharm Limited | 102 | 2016-04-06 | 2018-11-09 |
| Study Examining PrEP-001 in Subjects With Asthma PrEP-001, G-004 - Asthma | Phase 2 | Completed | Hvivo | 60 | 2015-12-11 | 2017-09-29 |
| Study Examining PrEP-001 in Healthy Subjects PrEP-001, Placebo Comparator - Influenza A H3N2 | Phase 2 | Completed | Hvivo | 66 | 2015-09-16 | 2019-11-12 |
Asthma (1) · Respiratory Tract Infections (1)
G004 compound (2) · Poly I-C (2)
United Kingdom (3)
John Efthimiou (2) · Cyrus Ghobadi, MD (1) · Litza McKenzie, MBChB BSc (1)